Please assess the completion status of the following clinical trial:

Trial Title: VSV-ZEBOV Geneva Vaccine Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has provided written informed consent before screening~* Adult male or non-pregnant, non-lactating female, ages 18 to 65 (inclusive) at the time of screening~* Free of clinically significant health problems, as determined by pertinent medical history and clinical examination at study screening~* Females of childbearing potential who are willing to use an effective method of contraception, from at least 7 days prior to vaccination through the end of the study period, and a double method from day 0 through day 28~* Males who are willing to use effective contraception from day 0 through day 28:~* Be willing to minimize blood and body fluid exposure of others for 7 days after vaccination~* Use of effective barrier prophylaxis, such as latex condoms, during penetrative sexual intercourse (avoiding the sharing of needles, razors, or toothbrushes, avoiding open-mouth kissing, be willing to refrain from blood donation during the course of the study)~Exclusion Criteria:~* Prior receipt of an Ebolavirus or Marburgvirus vaccine, a VSV-vectored vaccine, or any other investigational vaccine likely to impact on interpretation of the trial data~* Serologic evidence of prior Ebola exposure~* Has a household contact (HHC) who is immunodeficient, HIV-positive, pregnant, has an unstable medical condition in the opinion of the investigator (e.g., New York Heart Association Class ≥ II heart failure, severe debilitating asthma and/or chronic obstructive pulmonary disease)~* Works with livestock~* History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions~* Known allergy to the components of the BPSC1001 vaccine product~* Receipt of investigational product up to 30 days prior to enrollment or ongoing participation in another interventional clinical trial~* Receipt of licensed vaccines within 14 days of planned study immunization (30 days for live vaccines) or ongoing participation in another clinical interventional trial~* Acute or chronic, clinically significant psychiatric, hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the Investigator based on medical history, physical exam, and/or laboratory screening test~* Any baseline laboratory screening tests which is outside of acceptable range as defined in the protocol: ALT, AST, creatinine, hemoglobin, platelet count, total white blood cell count, urine protein, urine occult blood, urine glucose~* Serologic evidence of hepatitis C infection, evidence of active hepatitis B infection~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection, asplenia, cytotoxic therapy in the previous 5 years, and/or diabetes~* Any chronic or active neurologic disorder, including seizures, and epilepsy, excluding febrile seizures as a child~* Has a known history of Guillain-Barré Syndrome~* Has an active malignancy or recent (\< 10 years) history of metastatic or hematologic malignancy~* Suspected or known alcohol and/or illicit drug abuse within the past 5 years~* Pregnant or lactating female, or female who intends to become pregnant during the study period~* Administration of immunoglobulins and/or any blood products within the 120 days preceding study entry or planned administration during the study period~* History of blood donation within 30 days of enrollment or plans to donate within the study period~* Administration of chronic (\> 14 days) immunosuppressants or other immune-modifying drugs within 6 months of study entry~* Any other significant finding that, in the opinion of the investigator, would increase the risk of the individual's having an adverse outcome by participating in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- VSV-ZEBOV lower dose (Type: EXPERIMENTAL): One intramuscular (deltoid) injection of a lower dose (10\^7 plaque-forming units) of VSV-ZEBOV.~Study amendment (01.2015) : One intramuscular (deltoid) injection of a markedly lower dose (3x 10\^5 plaque-forming units) of VSV-ZEBOV
- VSV-ZEBOV higher dose (Type: EXPERIMENTAL): One intramuscular (deltoid) injection of a higher dose (5 x 10\^7 pfu) of VSV-ZEBOV.~Study amendment (01.2015) : interrupted
- Placebo (Type: PLACEBO_COMPARATOR): One intramuscular (deltoid) injection of normal saline (0.5 ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).